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a  b  s  t  r  a  c  t
As  people  age  they  become  increasingly  susceptible  to chronic  and  extremely  debilitating  brain  diseases.
The  precise  cause  of  the  neuronal  degeneration  underlying  these  disorders,  and indeed  normal  brain
ageing  remains  however  elusive.  Considering  the  limits  of existing  preventive  methods,  there  is  a  desire
to develop  effective  and  safe  strategies.  Growing  preclinical  and  clinical  research  in healthy  individuals
or  at  the  early  stage  of  cognitive  decline  has  demonstrated  the  beneﬁcial  impact  of nutrition  on cognitive
functions.  The  present  review  is  the most  recent  in a series  produced  by  the  Nutrition  and  Mental  Per-eywords:
ognition
reventive diet
ognitive decline
europrotection
euroinﬂammation
ognitive ageing
formance  Task  Force  under  the  auspice  of the  International  Life  Sciences  Institute  Europe  (ILSI  Europe).
The  latest  scientiﬁc  advances  speciﬁc  to  how  dietary  nutrients  and  non-nutrient  may  affect  cognitive
ageing  are  presented.  Furthermore,  several  key points  related  to mechanisms  contributing  to  brain  age-
ing,  pathological  conditions  affecting  brain  function,  and  brain  biomarkers  are  also  discussed.  Overall,
ﬁndings  are  inconsistent  and fragmented  and  more  research  is  warranted  to determine  the  underlying
mechanisms  and  to  establish  dose-response  relationships  for optimal  brain  maintenance  in  different
∗ Corresponding author at: International Life Sciences Institute Europe (ILSI Europe), Av E. Mounier 83, Box 6, 1200 Brussels, Belgium.
E-mail  address: publications@ilsieurope.be (J. Schuermans).
ttp://dx.doi.org/10.1016/j.arr.2016.09.010
568-1637/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
/).
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population  subgroups.  Such  approaches  are  likely  to  provide  the  necessary  evidence  to develop  research
portfolios  that will  inform  about  new  dietary  recommendations  on  how  to prevent  cognitive  decline.
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. Introduction
The signiﬁcant increase in average life expectancy is one of
ociety’s great achievements which has been associated with a
hift in the leading causes of illnesses from infectious to non-
ommunicable diseases. It is well known that the percentage of
opulations categorized as elderly (e.g. 65 years and older) will
ncrease dramatically in almost every country in the next few
ecades. By 2060, the elderly population will be expected to grow
rom 17.4% to nearly 30% worldwide (European Comission and
urostat, 2012). At the same time, there is a wealth of disparate
ata related to how nutrients, non-nutrient, food components
nd whole diets may  impact on cognitive health and ageing.
umerous epidemiological studies indicate that long-term intake
f a Mediterranean diet (emphasizing amongst others fruits, veg-
tables, and olive oil) correlates with better cognition in aged
opulations (Feart et al., 2010; Scarmeas et al., 2009; van de Rest
t al., 2015). Mechanistic investigations in vitro and in animal
odels have demonstrated that anti-inﬂammatory compounds in
lants stimulate neurogenesis and protect neurons from noxious
nsults. However, such studies could not be replicated in humans
Stangl and Thuret, 2009) and treatments with ibuprofen, or foods,
uch as turmeric, although decrease pro-inﬂammation biomarkers
nly rarely show any pro-cognition effects, at least in intervention
rials (Lee et al., 2013; Townsend and Pratico, 2005). Due to the lack
f highly sensitive cognitive test batteries and control for individual
ifferences, diets and nutrients are not proven to robustly alleviate
ognitive decline over short periods.
In the past 10 years, high-calorie/low-dietary ﬁbre diets and risk
nd incidence of diet-related diseases (i.e.  Type 2 Diabetes Melli-
able data on beneﬁcial effects of several ingredients or nutrients
(e.g. dietary ﬁbre, low-glycaemic carbohydrates, resveratrol and
docosahexaenoic acid (DHA)) suggest that their consumption may
decrease glycaemic spikes or improve plasma cholesterol or triglyc-
erides levels, thus having the potential to help prevent cognitive
decline (Greenwood, 2003; Greenwood and Winocur, 2005).
Randomized placebo-controlled trials (RCTs) are the gold stan-
dard to conﬁrm the effect of a nutritional intervention on cognitive
decline, maintenance or improvement. However, such trials may
be impossible to conduct for some nutrients, where subtle effects
are predicted to add up over decades and may  be signiﬁcantly inﬂu-
enced by individual differences in the rate of cognitive decline.
Currently, there are no dietary recommendations or accepted
health claims referring to age-related cognition on the foodstuffs
marketed. It may  be expedient to weigh evidence from pilot, cohort,
case control and animal studies, and evaluate these together, rather
than taking into account only RCTs. Some nutrients may  exhibit
stronger effects in conjunction with others, and thus, one aim of
this review is to weigh effects of nutrients in isolation, such as
DHA taken as ﬁsh oil supplements, versus combinations of partic-
ular bioactives such as found in the Mediterranean diet. Although
the present review is mostly focused on the role of nutrients in cog-
nitive decline, it also offers some insights about different aspects
related to the process of ageing. Thus, it highlights important
considerations about normal and pathological ageing and its mea-
surement through the use of biomarkers of cognitive status, as well
as metabolic conditions that are considered as risk factors for cog-
nitive decline. Therefore, the main goal of the present review is to
provide the most recent evidence from human observational and
intervention trials along with key mechanistic studies in cell andus (T2DM) or cardiovascular disease (CVD)) have been associated
ith age-related cognitive decline (Beydoun et al., 2008; Loef and
alach, 2013; Nepal et al., 2014; Whitmer et al., 2005). Avail-animal models, on the current state of knowledge on nutrition and
healthy brain ageing.
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. Normal and pathological decline in cognitive function
Major aspects of human cognitive function are inﬂuenced by
 variety of factors including genetics, lifestyle, nutrition, disease,
rauma, medicines, as well as both normal and pathological age-
ng. The group led by Salthouse (2010) has compiled a convincing
ody of evidence demonstrating that notable age-related decline in
ognitive function occurs in healthy individuals starting from the
ate 20s and continuing throughout the adult lifespan. Some head-
ine conclusions from this research are that such decline occurs in
ll individuals, concerns a wide range of major aspects of cogni-
ive function (i.e.  not simply memory) and are marked in nature
e.g. up to 2 standard deviations). Such ﬁndings have now been
idely replicated (Wesnes and Ward, 2001; Wesnes and Edgar,
014) and an important message is that the same aspects of cog-
ition which decline with ageing also decline (at a much greater
ate) both in Mild Cognitive Impairment (MCI) and in the dementias
Wesnes and Lenderking, 2012). Despite this compelling evidence,
here is little regulatory support for the development of medicines
o treat such declines. It is proposed that this time-based deteri-
ration to crucial aspects of mental ability in healthy individuals
hould receive the same aggressive treatments as other age-related
eclines (such as eyesight deterioration). Nevertheless, there was
 temporary surge of interest in this area over 25 years ago when
he National Institute of Mental Health (NIMH) workgroup deﬁned
perational criteria for age-associated memory impairment (Crook
t al., 1986). Then, over the next few years a variety of drugs
ere evaluated to treat this condition with some limited success
e.g. phosphatidylserine) (Crook et al., 1991). Criticism from some
uarters that the pharmaceutical industry was creating a new con-
ition simply to sell drugs to treat something which occurs in
ost individuals (O’Brien, 1999) led the industry to move away
rom this area and concentrate on pathological declines such as
CI, Alzheimer’s disease (AD) and other dementias (Wesnes and
ard, 2001). In fact, during the last 10 years the news for novel
rugs to treat MCI  and AD has been overwhelmingly negative. No
ovel treatment has been approved for treating AD, despite a mas-
ive worldwide research effort which has been overshadowed by
he failure of over a hundred putative treatments (Becker et al.,
008; Cummings et al., 2014; Mullard, 2012). This has led the
eld to move its focus to prodromal and even preclinical stages
f dementia, stimulated by diagnostic criteria designed in 2007 to
apture earlier stages based on early episodic memory loss along-
ide with biomarker evidence of disease pathology (Dubois et al.,
007). These criteria have been further reﬁned (Albert et al., 2011;
ubois et al., 2010) and the goal posts broadened considerably
ith operational research criteria for preclinical AD (Sperling et al.,
011). Preclinical AD is particularly relevant as the trials would
nvolve cognitively healthy elderly populations. Regulatory author-
ties have become proactive. In fact, in a recent publication authored
y the Food and Drug Administration (FDA) ofﬁcials, the point was
ade that in preclinical AD trials, where functional impairment
ould be difﬁcult to assess, it could be feasible to approve a drug
hrough the FDA’s accelerated approval pathway on the basis of
ssessment of cognitive function alone (Kozauer and Katz, 2013).
herefore, a regulatory avenue has been opened in addition to new
linical criteria, and large trials in preclinical AD are already under-
ay.
. Biomarkers of cognitive statusAD is a slowly progressive neurodegenerative disorder with
uration of several decades (Jack et al., 2011) showing 3 dif-
erent phases; one preclinical and asymptomatic, a second one
hen cognitive performance starts to decline, and the last phase Reviews 35 (2017) 222–240
characterized by the typical memory-dominant dementia syn-
drome, which impairs everyday activities and patient autonomy
(McKhann et al., 2011). In neuropsychiatric tradition, AD could
only be diagnosed in a clinical setting if dementia was present, but
a paradigm shift towards a more biologically deﬁned AD diagno-
sis has been observed in recent years. The new National Institute
on Ageing-Alzheimer’s Association (NIA-AA) guidelines conceptu-
alize AD as a progressive disorder including all possible stages
from pre-symptomatic to severely demented (Jack et al., 2011;
McKhann, 2011). This way of thinking implies that tissue changes
precede the onset of clinical signs by many years, and neuropatho-
logical lesions can be found in elderly individuals who presently
do not have, and may  not live long enough to ever suffer from
cognitive impairment and associated disability (Giaccone et al.,
2011).
During the past 30 years, a large body of evidence has
been accumulated indicating that a cascade of events related
to the faulty production, degradation and clearance of amyloid-
 protein (A)  lie at the heart of AD pathogenesis. Upstream
events within this cascade include the overproduction of the
amyloid- precursor protein (APP) caused by rare mutations
in the APP, PSEN1 or PSEN2 genes, malfunctioning of A-
degrading proteases and impaired clearance as a result of
ineffective active or passive transport mechanisms (Jack et al.,
2011). The imbalance between production and clearance results
in excessive amounts of A, which are believed to trigger a
sequence of subsequent, i.e.  downstream, pathological changes
such as loss of synapses and neurons, impaired glucose utilisation,
oxidative damage, brain metabolic reduction, tau hyperphos-
phorylation and associated neuroﬁbrillary tangle formation, A
deposition in plaques and eventually neurotransmitter changes and
widespread neurodegeneration. This complex cascade of patho-
logical events continues throughout the course of AD, leading to
an accumulation of structural and functional cerebral damages
causing the typical clinical feature of disease (Jack et al., 2011,
2010a,b).
The hope for disease modiﬁcation as well as technological
advances in biomarker discovery fuel the search for biological
indicators of the AD pathophysiological process, which can be
used to identify neurodegeneration independently of its clinical
manifestations (Hampel et al., 2010). Ideally, such a biomarker,
alone or in combination with other markers, would distinguish
between individuals with and without AD pathology. Furthermore,
pathophysiological markers may  also offer the added beneﬁt of
directly assessing response to treatment options that target core
processes of AD pathogenesis. However, biomarker evidence of
treatment efﬁcacy should not replace clinical evidence of patient
beneﬁt.
Currently available AD biomarkers can generally be grouped
into two categories. The ﬁrst category comprises markers that indi-
cate the type of pathology present, including cerebrospinal ﬂuid
(CSF) levels of A1-42, total tau (tTau) and phosphorylated tau
(pTau)181 (Blennow et al., 2010) and positron emission tomography
(PET) tracers of ﬁbrillar amyloid such as ﬂutemetamol, ﬂorbetapir,
ﬂorbetaben and Pittsburgh Compound B (Herholz and Ebmeier,
2011). The second category consists of markers that provide infor-
mation on the topography of pathological changes, such as MRI  and
ﬂuorodeoxyglucose PET (Dubois et al., 2010). Published evidence
consistently shows that these biomarkers, alone or in combination
with psychometric test results, offer an added value for the diagno-
sis of the early clinical stages of AD. Novel biomarkers that are more
closely related to the core pathophysiological processes of AD are
currently in development (Perneczky et al., 2014) such as soluble
forms of APP, which can be measured in CSF (Perneczky et al., 2011)
and blood (Perneczky et al., 2013).
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. Metabolic and molecular mechanisms contributing to
rain ageing
.1. Cardiometabolic risk factors
The role of cardiometabolic health, including vascular stiffness
nd reactivity in cognitive health and decline are being increas-
ngly recognized. In a 1-year longitudinal study in patients older
han 80 years higher aortic stiffness was associated with more
ronounced decline in cognitive function (Benetos et al., 2012),
nd microvascular function was signiﬁcantly impaired in demen-
ia patients as compared to controls (Khalil et al., 2007). Although,
he line between normal and pathological ageing may not be well-
eﬁned, certain metabolic alterations such as obesity or Type 2
iabetes mellitus (T2DM) may  account for an increased risk of
uffering age-related cognitive decline, especially in the elderly.
he dramatic global increase in the incidence of obesity over the
ast 50 years is having a large effect on the incidence of many
hronic diseases including T2DM and dementia. Indeed, more than
alf (52%) of the adult population in the 27 European Union (EU)
ember states are overweight (BMI = 25.0–29.9 kg/m2) or obese
BMI ≥ 30.0 kg/m2) (Eurostat statistics database et al., 2012) with
n average EU obesity incidence of 17% in adults (Eurostat statistics
atabase et al., 2012). An excess of adipose tissue and its associated
o-morbidities in middle-age, has emerged as a signiﬁcant risk fac-
or for age-related cognitive decline. A 27-year US cohort which
onsisted of overweight and obese individuals (aged 40–45 years)
howed an odds-ratio (OR) 95% conﬁdence interval (CI) of demen-
ia of 1.35 (1.14–1.60) and 1.74 (1.34–2.26), respectively, relative
o normal weight individuals (Whitmer et al., 2005). Comparable
ffect sizes of 1.5–2.0 OR have been documented in more recent
nalyses, including a meta-analysis, which reported an attributed
isk of 12% of total dementia and 21% of AD associated with obesity
n a US population (Beydoun et al., 2008). Indeed, including midlife
besity in forecast models typically results in a 10–20% higher
revalence of dementia (Loef and Walach, 2013; Nepal et al., 2014)
han the doubling of prevalence predicted by 2030 based only on
geing-related demographics (Alzheimer’s Disease International,
009).
Metabolic syndrome (MetS) and T2DM have comparable
mpacts on dementia risk and have been reported in overweight
nd obese individuals, respectively. For example, a relative risk
f 1.20 (1.02–1.41; 95% CI) of cognitive impairment was  evident
n MetS subjects as compared to healthy controls (Yaffe et al.,
004). Furthermore, in a recent meta-analysis including 19 stud-
es, subjects with diabetes presented higher risk for AD (relative
isk (RR):1.46, 95% conﬁdence interval (CI): 1.20–1.77), vascular
ementia (RR: 2.48, 95% CI: 2.08–2.96), any dementia (RR: 1.51,
5% CI: 1.31–1.74) and MCI  (RR: 1.21, 95% CI: 1.02–1.45) than
hose without (Cheng et al., 2012). Interestingly, these results also
howed that diabetes increases the risk for AD independently of
POE4 status, although subjects with both diabetes and APOE4 had
he highest risk for AD (Cheng et al., 2012).
A growing body of epidemiological evidence is also suggesting
hat metabolic syndrome (MetS) and its associated compo-
ents (impaired glucose tolerance, abdominal or central obesity,
ypertension, hypertriglyceridemia, and reduced high-density
ipoprotein cholesterol) may  be important in the development of
ge-related cognitive decline, mild cognitive impairment, vascu-
ar dementia, and AD (Frisardi et al., 2010; Panza et al., 2012b).
lthough some understanding exists regarding the role of glucose
nd insulin within the central nervous system (CNS), the physio-
ogical and molecular basis of the contribution of obesity and its
omorbidities to cognitive decline, along with causality and inde-
endence of associations are poorly understood (Freeman et al.,
014), but are likely to include: a) impaired vascular functionReviews 35 (2017) 222–240 225
and brain perfusion (Benetos et al., 2012; Elias et al., 2009; Khalil
et al., 2007; Picano et al., 2014), b) low grade inﬂammation, includ-
ing altered adipose tissue production of adipokines (Kiliaan et al.,
2014; Song and Lee, 2013), c) poor glucose tolerance and utilisation
(Lamport et al., 2009), and d) loss of insulin sensitivity indepen-
dent of the impact on glucose metabolism (Calvo-Ochoa and Arias,
2015; De Felice, 2013; Park et al., 2000; Williamson et al., 2012).
In this context, AD is currently proposed as an “insulin resistant
brain state” (Craft et al., 2013). In addition, insulin in the CNS
is largely derived from the periphery (pancreas) with some local
insulin produced by the dentate gyrus (hippocampus) and olfactory
system (Kuwabara et al., 2011). In neurons, insulin regulates energy
metabolism, differentiation, growth, survival, synaptic plastic-
ity and neurotransmission and promotes hippocampal long-term
potentiation (LTP), learning and memory (Bingham et al., 2002;
Calvo-Ochoa and Arias, 2015; Kuwabara et al., 2011; Skeberdis
et al., 2001). Therefore, a loss of insulin sensitivity would be pre-
dicted to negatively impact on these metabolic processes.
Neuroinﬂammation has been associated with the risk of devel-
oping dementia and cognitive decline (McGeer and McGeer, 1999;
Yaffe et al., 2003). In a longitudinal study, Yaffe and colleagues
examined the association between MetS and cognitive change in
elderly Latinos. Participants with MetS with high inﬂammation
(median serum CRP level ≥3.2 mg/L) had signiﬁcantly reduces cog-
nitive function, measured by using the Modiﬁed Mini-Mental State
Examination (3MS) than those without high inﬂammation. In this
study, the individual components of MetS were also examined
as predictors of cognitive change. The authors concluded that, in
elderly Latinos, the composite measure of metabolic syndrome is
a greater risk for cognitive decline than its individual components,
with the possible exception of impaired glucose control and high
blood pressure (Yaffe et al., 2007).
Interestingly, Solfrizzi and colleagues concluded in a longitudi-
nal Italian population-based sample, that MetS appeared to be a
risk factor of progression to dementia in MCI  patients. However,
it is unknown how MetS could increase the risk of dementia in
these patients (Solfrizzi et al., 2011). Unfortunately, in this study,
the number of events of progression to dementia in MCI  patients
was not sufﬁcient to allow the authors to analyse the effect of MetS
on the risk of developing a subtype of dementia.
4.2. Anaemia
The role of anaemia on cognition is still controversial and the
potential mechanisms by which anaemia could impact on cogni-
tive decline are still not understood (Andro et al., 2013). The main
hypothesis proposed, points to the role of the chronic low oxy-
genation of the aerobic cortical tissue, even more in the presence
of compromised compensatory processes due to the neurode-
generative or vascular pathology underlying MCI  (Andro et al.,
2013). Alternatively, anaemia has been suggested as a frequent
complication of chronic kidney disease which leads to decreased
erythropoietin levels that in turn may  increase the risk of neurode-
generation (Andro et al., 2013).
The number of studies investigating the relationship between
anaemia or haemoglobin concentration and dementia or cogni-
tive decline has increased in recent years. However, the results
of these studies are inconsistent (Lucca et al., 2008). Conﬂicting
results have been found in studies investigating the association
between anaemia or haemoglobin concentration and dementia or
AD or vascular dementia mainly due to not appropriately adjusted
confounding factors or inaccurate methodology (Lucca et al., 2008).
Consequently, larger size, prospective, more representative and
methodologically robust studies are needed to establish the pos-
sible effect of mild anaemia on cognition in elderly persons.
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.3. Oxidative stress
The brain is a highly metabolically active tissue that relies on
xidative phosphorylation as a way for maintaining energy. The
evel of oxidative stress plays a pivotal role in brain functioning
nd growing evidence suggests a delicate balance between free
adicals production and brain protection or damage (Chakrabarti
t al., 2011). A moderate oxy-radical production by the mitochon-
ria, reported as physiological level of oxidative stress, is known
o up regulate the mitochondrial biogenesis program and brain
ntioxidant capacity, and to act in brain protection. By contrast,
ccumulation of oxidative damages is a key mechanism of the age-
ng process and a common feature of ageing brain. That, together
ith age-related mitochondria decay, causes alterations of cellular
rchitecture within the brain, and raises the fact that uncontrolled
ree radical production is a major contributor to the loss of neuronal
omeostasis and neurodegenerative diseases development (Wang
t al., 2014).
.4. Neuroinﬂammation
It has been observed in animal models of AD and Parkin-
on Disease, that systemic inﬂammation generates an exacerbated
mmune response in the CNS through the local innate immune sys-
em. Then, the priming pattern triggered by activated microglia,
an be inﬂuenced not only by the sequence of neurodegeneration
ut also by the systemic inﬂammation or other secondary stimuli.
riming makes the microglia susceptible to a secondary inﬂamma-
ory stimulus, which can then trigger an exaggerated inﬂammatory
esponse (Perry and Holmes, 2014). Activated microglia has the
apacity to synthesize a wide range of pro-inﬂammatory and
nti-inﬂammatory cytokines and molecular mediators, which con-
ribute to the systemic inﬂammatory milieu and to the progression
f neurodegenerative disease (Perry, 2004; Perry et al., 2007). Dur-
ng neurodegenerative events, neural damage leads to a loss or
own regulation of neural ligands that bind to inhibitory recep-
ors on the microglia, resulting in a reduced microglia inhibition.
riming of macrophages has been widely studied in vitro follow-
ng the exposure to IFN-γ and lipopolysaccharide (Schroder et al.,
006). Low doses of lipopolysaccharides are sufﬁcient to trigger
icroglia activation and sickness behaviour in both humans and
on-human primates (Brydon et al., 2008; Hannestad et al., 2012;
arrison et al., 2009).
Nevertheless, other molecules expressed in the injured brain
uch as the colony-stimulating factor-1 (CSF-1) (Chapoval et al.,
998) and C C motif chemokine 2 (CCL2) (Bhattacharyya et al.,
002; Rankine et al., 2006) can also prime microglia. Activation of
SF-1 receptor (CSF-1R) by CSF-1 and IL-34 (Greter et al., 2012;
ang et al., 2012) drive microglia proliferation (Gomez-Nicola
t al., 2013), which is signiﬁcantly important since the primed
tate and the increased number of microglia both contribute to the
xaggerated response observed in the brain in neurodegenerative
isorders.
In addition, mutations in CSF-1R also lead to important white
atter damages associated with progressive dementia but the
isease onset and severity strongly depend on the mutation
Nicholson et al., 2013). The effects of the mutation on white mat-
er region along with the fact that microglia remains more in white
atter than in grey matter, suggest that microglia may  have an
mportant role in myelin or axonal homeostasis.
Ageing, as the main risk factor for AD development, occurs
ith a chronic, low-grade systemic upregulation of the proin-
ammatory T helper type 1 response and a relative decline in
he anti-inﬂammatory T helper type 2 response (Franceschi et al.,
007). A study which examined brain samples from patients with
ild or late-stage AD investigated the type of the inﬂammatory Reviews 35 (2017) 222–240
response (M1- or M2-like: CNS activated microglia corresponding
to ‘cytotoxic’ and ‘repair’ subpopulations of macrophages in other
organs) and tried to ﬁnd serum markers that were associated with
these two  phenotypes (Sudduth et al., 2013). Noticeably, the M1-
like state was  associated with increased levels of CCL3 and the
M2-like state with increased serum levels of IL-1 receptor antago-
nists.
It is well known that in the ageing population, an increas-
ing number of individuals have more than one systemic disease
(Barnett et al., 2012), which indicates that systemic inﬂammation
has a relevant importance as a risk factor for AD. The group of Perry
et al. has demonstrated that systemic inﬂammation and acute infec-
tions are associated with an enhanced rate of cognitive decline
(Holmes et al., 2009) and increased symptoms of sickness in AD
patients (Holmes et al., 2011).
Therefore, according to all these data, the monitoring and
prompt treatment of systemic disease, inﬂammation and infection
may  delay neurodegenerative disease progression and improve
quality of life (Perry and Holmes, 2014).
4.5. AMPK signalling and autophagy
Although, the precise neurobiological origin of dementia
remains controversial, systems medicine approaches integrating
recent advances in molecular technologies with computational
methods are able to address this complexity and to identify key
molecular hubs relevant for neurodegenerative dementia. These
approaches, supported by the fast growing knowledge of human
interactome, offer a platform to systematically explore not only
the molecular complexity of a particular disease but also the
molecular relationships among apparently distinct diseases. The
group of Caberlotto et al. (Caberlotto et al., 2013) applied these
novel systems biology approaches not only to clarify the molecu-
lar basis of AD, but also to characterize the molecular alterations
of the subgroup of neurodegenerative disorders with the shared
core symptom of dementia. By convergent analysis of multi-
dimensional datasets, their study on AD revealed a major role of
metabolism and, predominantly, of AMP-activated kinase (AMPK)
as a central dis-regulated process in AD. AMPK is a core sig-
nalling pathway in cellular homeostasis and crucial regulator of
energy metabolism. Through the examination of neurodegenera-
tive dementias, they integrated not only the current knowledge on
the speciﬁc diseases, but also the molecular targets of drugs for the
treatment of dementia. This study underlined once more the role
of AMPK signalling and autophagy, a self-degradative process that
is important for balancing sources of energy in response to nutri-
ent stress, as the molecular basis of neurodegenerative dementia
(Caberlotto and Nguyen, 2014). Similar results were obtained from
the integrative analysis of AD and T2DM, two multifactorial dis-
eases of ageing with marked common pathophysiological features,
which conﬁrmed the autophagy pathway as the molecular mecha-
nism altered in both diseases (Caberlotto and Nguyen, 2015).
5. Prevention of cognitive decline through nutritional and
other lifestyle interventions
Preclinical and clinical studies provide valuable data regarding
the effect of particular dietary patterns and/or speciﬁc nutrients
on cognitive function. For example, deleterious dietary habits
(overfeeding, high caloric/low dietary ﬁbre diet or consumption
of low antioxidant nutrients) and sedentary lifestyle, or emo-
tional stress, have been reported as key environmental factors for
oxidative stress and brain disorders (Martin et al., 2006; Mattson,
2012). Insulin resistance (IR) which is found in overweight, MetS,
and T2DM individuals is one of the leading causes of oxidative
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tress. Given the negative effects of IR, inﬂammation and oxidative
tress in brain, several dietary components, acting as antioxi-
ant, anti-inﬂammatory and/or insulin action potentiating factors,
ould positively participate in a preventive nutritional strategy
or healthy ageing of brain. It is therefore necessary to increase
esearch on the beneﬁts of nutrition and healthy eating habits
n order to identify the best dietary recommendations in human
opulation. These will enable the prevention or delay of diseases
nd disability and increase quality of life in the elderly (Roman-
in˜as and Serra-Majem, 2014). Among existing dietary patterns,
dherence to a Mediterranean diet is associated with less cognitive
ecline, dementia, or AD (Cao et al., 2015; van de Rest et al., 2015)
nd ﬁts the notion of a healthy dietary pattern (Maillot et al., 2011).
or example, a meta-analysis showed that greater adherence to a
editerranean-style dietary pattern during older adulthood was
ssociated with a lower risk of developing several different health
utcomes such as CVD, neurodegenerative disorders, cancer and
verall mortality (Soﬁ et al., 2010). In general, the Mediterranean
iet is characterized by a high intake of vegetables, fruits, cereals,
uts and olive oil (as the principal source of added fat), a mod-
rate intake of ﬁsh and alcohol (mostly wine), and a low intake
f dairy products, red meat and meat products (Bach-Faig et al.,
011). Higher adherence to a Mediterranean-style diet was asso-
iated with higher intakes of several antioxidant nutrients, and
ther food bioactives such as polyphenols, which are present in
ruits, vegetables, cereals and beverages such as wine, coffee and
ea. Particularly, the role of coffee and caffeine consumption in
ater-life cognitive decline and dementia has been examined in a
ecent systematic reviewed by Panza and colleagues including 28
tudies, which reported a potential correlation of moderate con-
umption of coffee or caffeine-rich beverages with a reduction in
ognitive decline (Panza et al., 2015). Consistent with this, Santos
nd colleagues in their systematic review and meta-analysis of caf-
eine and cognitive impairment/decline conducted in nine cohort
nd two case control studies reported a nonsigniﬁcant relative risk
RR) of 0.98 [95% Conﬁdence Interval (CI): 0.87–1.11], with mod-
rate heterogeneity (Santos et al., 2010). Although, there was  a
ack of a linear dose-response relationship and an association was
ot found in all cognitive domains investigated, most of reviewed
opulation-based studies pointed to a neuroprotective effect of
offee or caffeine consumption against cognitive impairment and
eurodegenerative disorders, with a stronger effect among women
han men  (Arab et al., 2013; Liu et al., 2016; Panza et al., 2015;
antos et al., 2010).
On the other hand, contrasting ﬁndings also exist between
lcohol consumption and reduced risk of age-related cognitive
ecline (Panza et al., 2012a). One recent meta-analysis from epi-
emiological longitudinal studies on older adults suggested that,
ight-to-moderate alcohol (usually wine) consumption was asso-
iated with a 38% reduced risk of incident overall dementia
Peters et al., 2008). In addition, another meta-analysis reviewed 15
rospective studies including older adults and revealed that light-
o-moderate alcohol intake was correlated with a 25–28% reduction
n risk of AD, vascular dementia, and overall dementia as compared
o alcohol abstinence (Anstey et al., 2009). Finally, a more recent
ystematic review and meta-analysis, which reviewed 74 studies
n older individuals, found that moderate intake of alcohol reduced
ognitive impairment or dementia risk, whereas heavy drinking
as associated with a trend toward a higher risk for cognitive
mpairment and dementia (Neafsey and Collins, 2011). Altogether
hese studies indicate that light to moderate alcohol consumption
ay  protect against AD and dementia. However, the importance of
rinking patterns and speciﬁc beverages remain unknown (Ilomaki
t al., 2015).Reviews 35 (2017) 222–240 227
5.1. Speciﬁc nutrient levels and age-related cognitive decline
Examination of biochemical indicators of diet in subject popu-
lations at high risk for dementia can serve to develop an evidence
base for distinct nutritional requirements for the prevention of
cognitive decline. In addition, comprehensive assessment of nutri-
tional status beyond single or few nutrients can provide insight into
the interactive features between nutrients that may  be relevant to
translational efforts. Thus, these “nutrient biomarker patterns” can
be related to risk for pathological, structural and metabolic changes
that precede cognitive decline and provide insight into mechanism.
One of the earliest structural changes in the brain that precedes
cognitive decline is the accumulation of paraventricular and sub-
cortical deep white matter hyperintensities (WMH). These WMH
may  indicate a breakdown of the blood-brain barrier via ischemic
changes and demyelination of axons (Prins and Scheltens, 2015)
and are a risk factor for cognitive decline. The CSF/plasma ratio of
blood derived albumin is another indicator of BBB function. Here
an increase in the CSF/plasma albumin ratio indicates BBB break-
down (Chen, 2011). The BBB impairment is prevalent in about
25% of autopsy conﬁrmed AD cases and is associated with more
rapid decline over time. Speciﬁc nutrient concentrations in the
CSF appear to be inﬂuenced by BBB integrity and this loss of
CNS concentration is associated with worse prognosis in AD cases
(Bowman, 2012). Another study has demonstrated that BBB func-
tion is modiﬁable through vitamin therapies (Lehmann et al., 2003).
Thus maintaining BBB health may  be one target for nutritional
therapies aimed at maintaining cognitive function. This area and
underlying changes at the BBB that inﬂuence transport and concen-
tration of nutrients in the brain remain an open area for research.
One report applied a data-driven approach to derive nutrient
biomarker patterns (NBPs) in the Oregon Brain Ageing Study. The
study included 104 subjects with a mean age of 87 years-old and
free of dementia at baseline. Eight distinct NBPs were identiﬁed and
examined in relation to domain speciﬁc cognitive function and MRI
measures of brain ageing (Bowman et al., 2012). The results were
remarkable in the sense that it appeared that some NBPs were asso-
ciated with global cognition and others mapped more to certain
cognitive faculties only. This would suggest that certain nutrient
combinations operate on general mechanisms in the brain while
others are more discrete. For example, two NBPs were associated
with more favourable cognitive and MRI  measures: one vitamin
proﬁle (high plasma B vitamins, antioxidants C, and E and vita-
mins D) and another high in plasma -3 fatty acids. The vitamin
proﬁle explained a signiﬁcant portion of variance in global cogni-
tive function and particularly, attention, visuospatial and executive
functions. It was also associated with less total brain atrophy, a phe-
nomenon that can be driven by Alzheimer’s type pathology. The
omega -3 pattern appeared more important to vascular aspects
(WMH  volume and executive functions known to be sensitive to
WMH  accumulation). A third pattern characterized by high trans-
fat was associated with less favourable cognitive functions across
several domains and more total brain atrophy. Memory function
was best in those with higher plasma lutein and HDL cholesterol
(Bowman et al., 2012). The NBPs altogether explained 17% of the
total variation in global cognitive function and 37% of total variation
in total brain volume. These data suggest that biochemical indica-
tors of diet capture magnitudes of effect well beyond what we are
accustomed to observing in nutrition research. One explanation is
that the nutrient biomarker pattern analysis appreciates “synergis-
tic” features, and another is that misclassiﬁcation bias of nutritional
exposure is reduced in comparison to more conventional methods
subject measures of diet in older adults. In a longitudinal study of
older adults at risk for dementia and followed over 4 years, plasma
levels of the two  long chain polyunsaturated fatty acids EPA and
DHA were associated with less executive function decline and that
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elationship appeared to be mediated by WMH  burden (Bowman
t al., 2013). These studies suggest that nutrient biomarker pattern
nalysis is a fruitful strategy for studying nutrition, metabolism and
ementia. What and how nutrients inﬂuence the neurobiology that
ontributes to age-related cognitive decline warrants much more
esearch. Combining human induced pluripotent stem cells (iPS)
ells biology, molecular and nutritional neuro-epidemiology and
linical trials is a way forward.
.2. Nutritional assessment for disease prevention
The purpose of nutritional assessment is to well-characterize
he dietary patterns of individuals, and to assess their exposure
o nutrients and the hundreds of non-nutrients provided by the
iet, for example phytochemicals, food additives, and food con-
aminants. Then, this information can provide scientiﬁc evidence
or the role of dietary factors on human health and well-being.
ther purposes of nutritional assessment are to identify popula-
ion groups who do not have an adequate nutrition for disease
revention and to develop nutrition programs for at risk popu-
ations in order to monitor their impact. Nutritional assessment
s still a huge challenge, due to the extraordinary heterogeneity
nd variability of food choices, and our limited knowledge of the
omposition of foods beyond the ∼60 essential nutrients. Ideal
ethods of nutritional assessment should be accurate, sensitive
nd applicable to many populations. Currently, available methods
all into four categories: 1) anthropometric methods, 2) clinical
xamination, 3) questionnaires, and 4) biomarkers. Anthropomet-
ic methods such as body mass index (BMI) measurement have
een considered as indicators of the adequacy of energy intake,
ut the correlation with diet quality is very questionable. Clinical
xamination has been used to diagnose severe vitamin or mineral
eﬁciencies. However, this method is not appropriate for mild deﬁ-
iencies. Today, dietary assessment is often conducted using Food
requency Questionnaires (FFQs), where subjects must remember
heir intake of 10–300 food items over the previous year. Multiple
4 h recalls and food records are more precise but more expensive
nd therefore, other new technologies have been developed. Now,
eb-based questionnaires are applied in large cohort studies, as
n the French NutriNet-Santé cohort which includes over 200,000
ubjects (Hercberg et al., 2010). Smart phone applications also seem
romising. Nevertheless, even with more technology, question-
aires have inherent limitations due to self-reporting (Maillot et al.,
011; Roman-Vin˜as and Serra-Majem, 2014; Soﬁ et al., 2010) and
re susceptible to recall bias. Even if statistical techniques have
een developed to correct measurement errors, questionnaires,
specially FFQs, are suspected to markedly attenuate associations
xisting between dietary factors and health outcomes (Bach-Faig
t al., 2011). The last approach for nutritional assessment is the
se of biomarkers, which are quantiﬁed through targeted analy-
es of bioﬂuids or tissues (Arts and Hollman, 2005; Scalbert et al.,
005). Biomarkers are independent of all the errors associated
ith questionnaires. Today, only a limited number of validated
iomarkers of food intake have been use in epidemiology (Arts and
ollman, 2005; Scalbert et al., 2005), for example plasma vitamin
 or carotenoids for fruit and vegetable intake, alkylresorcinols for
hole grains, and urine methyl-histidine for meat. Some polyphe-
ols have also been occasionally used as biomarkers of intake for
heir main dietary source (van Dam et al., 2013), for example resver-
trol for red wine or hesperetin for orange (Cassidy et al., 2013).
hese biomarkers have been discovered using a hypothesis-driven
pproach which means that a speciﬁc compound of the food was
reviously known, its bioavailability was documented and then a
eliable method of analysis could be developed. However, validated
arkers discovered with this approach do not cover the large diver- Reviews 35 (2017) 222–240
sity of food in the human diet, and many new biomarkers are still
needed.
In the last decade, metabolomics has emerged as a data-
driven approach for biomarker discovery. The concept of the food
metabolome has been deﬁned (Scalbert et al., 2014) which repre-
sents all the metabolites present in human tissues and bioﬂuids
that directly derive from the digestion and metabolism of food
chemicals. The food metabolome is affected by both, the dietary
habits and the metabolic capacity of individuals.As an example, a
medium-term controlled intervention study was  conducted to ﬁnd
biomarkers of citrus fruits intake (Pujos-Guillot et al., 2013) where
12 volunteers consumed 500 mL/day of orange juice or control
drink for one month, in a cross-over design. The urine metabolomes
analysed by non-targeted high resolution mass spectrometry were
compared at the end of the experimental period. Some expected
candidates biomarkers of orange juice intake were identiﬁed such
as the glucuronides of the citrus ﬂavanones, hesperetin and narin-
genin but new candidates were also found, including some terpene
metabolites as well as proline betaine, which seemed even more
sensitive than the ﬂavanone metabolites (Pujos-Guillot et al., 2013).
Proline betaine has been validated in independent studies, quanti-
ﬁed in a range of foods and was found almost exclusively in citrus
fruits (Scalbert et al., 2014). This case-study example and many oth-
ers now demonstrate that metabolomics is an efﬁcient approach to
discover new reliable biomarkers of food intake in a data-driven
approach. In total, more than 145 candidate biomarkers have been
proposed for about 20 foods through these food metabolome stud-
ies, and interestingly about 75% were phytochemical metabolites
(Scalbert et al., 2014). These candidate metabolites must be vali-
dated as it has been done for proline betaine.
Since interventional studies for all the foods of the human diet
are not feasible, the use of cohort samples to identify candidate
intake biomarkers for a range of foods at the same time can be
performed. The Phenotyping using Metabolomics for Nutritional
Epidemiology (PhenoMeNEp) project (Rothwell et al., 2014) used
the SU·VI.MAX2 cohort which is a well-characterized cohort of
French adults and identiﬁed the strongest discriminant of coffee
intake as Atractyligenine glucuronide, a phase II metabolite of a
diterpene, which contributes to the bitter taste of roasted cof-
fee and which has never been reported in signiﬁcant amounts in
any other food sources (Rothwell et al., 2014). Two others strong
discriminants were alkaloids, the diketopiperazine cyclo (isoleucyl-
prolyl) and trigonelline. The three biomarkers were classiﬁed
as excellent biomarkers when their performance was assessed
using receiver-operating characteristic (ROC) curves test. Certainly,
metabolomics-derived coffee biomarkers will be used in the com-
ing years, in particular to study the impact of coffee on cognition.
Therefore, proﬁling of urine or plasma metabolomes in inter-
ventions or cohorts studies is efﬁcient to discover new candidate
biomarkers of food intake with a data-driven approach. A large
initiative, the FoodBAll project (http://foodmetabolome.org/) has
recently been funded by the European Joint Programming Initia-
tive Healthy Diet for Healthy Life, to identify a large range of new
nutritional biomarkers using metabolomics and to develop a har-
monized scheme for their validation. Beyond biomarker discovery,
food metabolome proﬁling covering a wide range of bioactives and
biomarkers of intake in bioﬂuids may  become a new method for
nutritional assessment, once the current technical difﬁculties for
rapid and complete proﬁle annotation will be overcome.
5.3. MicronutrientsAs reported by numerous studies in animals and humans, essen-
tial antioxidant trace elements such as Zinc (Zn), Selenium (Se)
and/or insulin sensitizers (Chromium (Cr), Zn) are deeply impli-
cated in brain protection. Selenoproteins, i.e.  Selenoprotein P and
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lutathione peroxidase, protect brain cells against oxidative stress.
 low Se status increases the risk of cognitive decline. The greater is
he decrease in plasma Se, the higher is the probability of cognitive
ecline as indicated in the study of Akbaraly et al. (Akbaraly et al.,
007). A potential preventive relevance for an optimal Se status
an be therefore speculated to maintain a healthy brain [63]. How-
ver, there is an absence of consistent clinical evidence regarding
hether Se supplementation is beneﬁcial for the treatment of AD
Loef et al., 2011).
Zn also acts positively on brain health by improving insulin sen-
itivity and reducing inﬂammation and oxidative stress. However,
o far no beneﬁts on ageing brain are reported after Zn supple-
entation in humans and even a potential neurotoxic effect of Zn
ccumulation has been observed in AD patients (Nuttall and Oteiza,
014).
Cr deﬁciency has resulted in insulin resistance and increased
xidative stress (Roussel et al., 2007). Indeed, in insulin resistant
tates (T2DM and MetS), increased Cr intakes are associated with
mproved cognitive functions (Krikorian et al., 2010).
.4. Polyphenols and polyphenol-rich diets
A number of studies have observed protective associations
etween dietary polyphenols and the prevention of age-related
hronic diseases such as CVD, diabetes, cancers, osteoporosis and
eurodegenerative diseases (Arts and Hollman, 2005; Scalbert
t al., 2005; van Dam et al., 2013). The strongest evidence of health-
rotective properties is for CVDs (Cassidy et al., 2013; Hooper
t al., 2008; McCullough et al., 2012). However, the well-known
iases and measurement errors of dietary assessment tools make
he precision and accuracy of dietary intake estimations difﬁcult,
nd therefore, the associations observed between polyphenols and
ealth are compromised. As a result, it is still challenging to develop
ersonalized diet-related recommendations for dietary polyphenol
ntake, and further research on the identiﬁcation and validation of
ew nutritional biomarkers is warranted (Zamora-Ros et al., 2012).
In the epidemiologic InCHIANTI study (Invecchiare in Chi-
nti, ageing in the Chianti area), the group of Andres-Lacueva
nvestigated the associations between total urinary polyphenols,
s biomarkers of total dietary polyphenols (Zamora-Ros et al.,
011), and all-cause mortality over a 12-year period among older
dult participants (Zamora-Ros et al., 2013). Recently, they also
nvestigated the associations between total polyphenols and cog-
itive decline over a 3-year follow-up in older participants free of
ementia at baseline (Rabassa et al., 2015). In these studies, they
bserved that participants who consumed a diet rich in polyphe-
ols (>600 mg/d) reduced the risk of all-cause mortality and the
isk of cognitive decline in global cognitive function (using the mini-
ental state examination), and in attention (using the Trail Making
est A), by 30%, 47% and 48%, respectively. By contrast, they did not
educe the risk of decline on executive function measured with the
rail Making Test B, as compared to those who consumed diets low
n polyphenols (<500 mg/d). However, no association was observed
etween total urinary resveratrol metabolites, a biomarker of red
ine consumption, and all-cause mortality (Rabassa et al., 2015).
In addition, research on ageing effects has revealed several sig-
alling pathways which have been experimentally demonstrated
o be involved in the regulation of the ageing process (Salminen and
aarniranta, 2012). The central effects of these polyphenols, at the
ranscriptomic level conﬁrmed the involvement of speciﬁc molec-
lar component of the AMPK-autophagy systems also in neuronal
nd glial cells (unpublished data). The modulation of AMPK and
utophagy could potentially prevent not only neurodegeneration,
ut also, in more general terms, it could promote healthy cognitive
geing.Reviews 35 (2017) 222–240 229
Cinnamon polyphenols also deserve a special attention since
they have been reported to reverse in vitro Tau protein aggregation
and break up Tau ﬁlaments (Peterson et al., 2009). Interestingly,
cinnamon added to the diet also counteracts the increase of amyloid
precursor protein (APP) and Tau protein induced by a high fat/high
fructose diet in the rat brain (Anderson et al., 2013).
Polyphenols intake is associated with consumption of fruits
such as grapes, apples, pears, cherries and various berries contain
between 200 and 300 mg  of polyphenols per 100 g of fresh weight
(Llorach et al., 2012). Moreover, a cup of tea or a large cup of cof-
fee contains around 100 mg  of polyphenols. Red wine, chocolate,
legumes and nuts also contribute to the polyphenol intake. Recent
development in analytical techniques and in metabolomics should
allow the measurement of large sets of polyphenol metabolites as
biomarkers of usual dietary polyphenol intake (Llorach et al., 2012).
This will be essential if we are able, ﬁnally, to make dietary rec-
ommendations regarding polyphenols for improving the autonomy
and quality of life in older people.
5.5. Flavonoids
Amongst polyphenols, the ﬂavonoid subclass has been exten-
sively studied. Given the wealth of available data for these
phytochemicals, we  decided to present those as a separate para-
graph. Flavonoids, found in a variety of fruits, vegetables and
beverages, have been recognized as promising agents capable
of inﬂuencing different aspects of synaptic plasticity resulting
in improvements in memory and learning in both animals and
humans (Del Rio et al., 2013; Spencer, 2008; Williams and Spencer,
2012).
Accumulating evidence suggests that certain dietary ﬂavonoids
might delay the onset and/or slow the progression of AD (Williams
and Spencer, 2012), but the precise identity of the bioactive form(s)
involved is unknown and critical information about bioavailability
and metabolism has hindered progress in the ﬁeld. Despite signif-
icant advances in our understanding of the biology of ﬂavonoids
over the past 15 years, they are still mistakenly regarded by many
as acting simply as antioxidants. Yet, ﬂavonoids are much more
likely to combat neuronal dysfunction and toxicity by recruiting
anti-apoptotic pro-survival signalling pathways, increasing antiox-
idant gene expression, and reducing A pathology (Williams et
al., 2004; Williamson et al., 2012). There is, however, a lack of
consensus as to the precise identities of the ﬂavonoids capable of
exerting these effects, partly because ﬂavonoids have notoriously
poor bioavailability and are extensively metabolised in vivo, but
also because most in vitro studies use concentrations that are at
least 100 fold higher than those found following dietary admin-
istration. The group of Williams has started to address some of
these limitations by adopting unbiased in vitro screening strategies
using ﬂavonoids at concentrations that are potentially achiev-
able in humans to mimic  more closely what occurs in vivo as a
ﬁrst step towards identifying possible dietary interventions for
AD (Cox et al., 2015). Using an APP-GAL4 gene reporter assay in
primary rodent neurones to screen modulators of APP processing
they identiﬁed a number of ﬂavonoids that potently inhibit -
secretase activity. Most notably, the ﬂavanols (−)-epicatechin (EC)
and epigallocatechin reduced -secretase activity and A produc-
tion at nanomolar concentrations and reductions in A pathology
were also observed following oral administration of EC to APP-PS1
mutant mice.
Since EC is readily absorbed and circulates primarily as glu-
curonidated, sulfated, and O-methylated forms in human plasma,
the observed bioactivity is most likely to reside in an EC metabo-
lite. Therefore, Williams’ hypothesis was that dietary EC, acting
as a prodrug, or alternatively a synthetic EC analogue based on a
metabolite, had the potential to be developed into a prophylactic
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ietary supplement for AD. The molecular mechanism underlying
his reduction in A production both in wild-type neurons and in
 transgenic model of AD is not clear but Williams et al. presented
vidence suggesting that EC inhibits the -site amyloid precursor
rotein cleaving enzyme 1 (BACE1) (Cox et al., 2015).
A large body of evidence has also emerged from human
ntervention studies demonstrating that the consumption of
avonoid-rich foods is associated with cognitive beneﬁts (for a
eview see (Macready et al., 2010; Williams and Spencer, 2012)).
he mechanisms by which ﬂavonoids exert these actions on cog-
itive performance are being elaborated, with evidence suggesting
hat they may  modulate the activation status of neuronal recep-
ors, signalling proteins and gene expression (Rendeiro et al., 2012,
013; Williams et al., 2008). Although whether these effects are
ediated directly (i.e.  within the brain) or from the periphery is
urrently unknown.
There is considerable evidence suggesting that neuronal activ-
ty during cognitive performance is tightly coupled to increases
n regional blood ﬂow, a process known as cerebrovascular cou-
ling (Attwell et al., 2010). Such processes are primarily mediated
y nitric oxide (NO) generated by the activation of both endothe-
ial nitric oxide synthase (eNOS in endothelium) and neuronal
itric oxide synthase (nNOS in neurons) (Toda et al., 2009). In
articular, NO derived from eNOS activation contributes to cere-
ral arterial dilatation, by migrating to vascular smooth cells and
ncreasing blood ﬂow at the blood-brain interface (Atochin and
uang, 2011). Furthermore, there is increasing evidence suggesting
hat the cerebrovascular response is also mediated by NO liberated
rom nNOS-containing neurons adjacent to intra-cerebral arteri-
les and capillaries (Schroeter et al., 2006).
There is substantial evidence which supports the beneﬁcial
ffects of ﬂavonoids, in particular ﬂavanols (Schroeter et al.,
006, 2010) and anthocyanins (Rodriguez-Mateos et al., 2013) on
eripheral vascular function and blood ﬂow (measured using ﬂow
ediated dilatation). These effects are mediated by the actions
f absorbed ﬂavonoid metabolites on NO bioavailability, via their
otential to activate eNOS (Schroeter et al., 2006) and/or inhibit
ADPH oxidase activity (Rodriguez-Mateos et al., 2013). Such
mprovements in vascular function occur acutely e.g.  ﬂavanols
cocoa, tea; 1–3 h) (Schroeter et al., 2006) and anthocyanins (blue-
erry; 1–2 h and 5h+) (Rodriguez-Mateos et al., 2013), are in the
ame timeframe and show cognitive improvements using similar
nterventions type. Furthermore, ﬂavonoid-induced improvements
n spatial memory in animal models (Rendeiro et al., 2012; Williams
t al., 2008) share similarities with those of exercise-induced alter-
tions in synaptic plasticity in the brain (Bechara and Kelly, 2013;
otman et al., 2007), as both involve the activation of Akt/PKB and
he increased expression of BDNF (Spencer, 2009). Indeed, Akt/PKB
ctivates both eNOS and nNOS, via increases in intracellular Ca2+
evels in endothelial and neuronal cells, respectively (Dimmeler
t al., 1999; Rameau et al., 2007) and thus, that may  represent a
ommon path by which ﬂavonoids and exercise facilitate cognitive
mprovements. The central role that NO plays in ﬂavonoid-induced
mprovements in human cognition and cerebral blood ﬂow has
een explored by the use of NOS inhibitors, which block the conver-
ion of l-arginine to l-citrulline and inhibit NO production (Iadecola
t al., 1994). Future studies should utilize l-arginine analogues
uch as nitro-l-arginine methyl ester, nitro-l-arginine, and L-N
-mono-methyl-arginine (L-NMMA) to help provide information
n the role of NO and blood ﬂow in mediating cognitive activ-
ty of polyphenols. Use of L-NMMA  in humans has been shown to
esult in a fall in cerebral blood ﬂow (Shabeeh et al., 2013) with-
ut altering basal metabolic activity (Kelly et al., 1994). The use of
OS inhibitors in vivo has the potential to assess the contribution
hat NO plays in mediating increases in cerebral blood ﬂow and
yperemic responses to cognitive activity in response to ﬂavonoid Reviews 35 (2017) 222–240
intervention. Applying such an approach to polyphenol clinical
trials will provide a clearer mechanistic understanding of how
ﬂavonoid intake acutely mediates cognition and how such transient
blood ﬂow alterations may  underpin longer-term improvements in
humans.
Recent datasets indicate that high ﬂavanol intake (495 mg) is
associated with improvements in human executive function and
episodic memory at 2 h post-consumption, compared to a low
ﬂavanol control (23 mg)  (Lamport et al., 2015). Similar data fol-
lowing anthocyanin intake (755 mg;  delivered and controlled as
blueberry) indicate that cognitive improvements are manifested
at 5 h post intake reaching signiﬁcance already at 1 h (Lamport
et al., 2015). The time-course of these cognitive effects, along
with Spencer’s recent peripheral vascular function/blood ﬂow data,
using ﬂow-mediated dilatation (FMD) (Rodriguez-Mateos et al.,
2013) suggested that the modulation of peripheral blood ﬂow and
cerebrovascular blood perfusion by ﬂavanol-rich foods may medi-
ate acute improvements in cognition. In support of this hypothesis,
recent pilot data indicate that ﬂavanol intake (495 mg) is capa-
ble of increasing cerebral blood perfusion within select regions of
the brain, as measured by arterial spin labelling (Lamport et al.,
2015) in a timeframe consistent with both peripheral vascular and
cognitive test performance. Further, a memory testing procedure
known as pattern separation has recently been identiﬁed which has
the potential to demonstrate therapeutic response in men  to com-
pounds which promote hippocampal neurogenesis (Bakker et al.,
2008; Yassa et al., 2011). A paper has just appeared demonstrating
that one of such tests was able to identify positive effects of a high-
ﬂavanol cocoa preparation in elderly healthy volunteers (Brickman
et al., 2014). In this study, improved cognitive function with the
cocoa preparation was accompanied by functional magnetic reso-
nance imageing (fMRI) evidence of enhanced activity in the dentate
gyrus which is the hippocampal site responsible for neurogenesis.
However, to date, no cause-effect relationship has been investi-
gated between ﬂavonoid intake, vascular function and cognitive
performance. In addition, very little is known about the longer-term
effects of ﬂavonoids on cognitive function in humans, or whether
such effects may  be sustained in the absence of intake, despite there
has been a wealth of animal data in support of potential longer term
efﬁcacy (Corona et al., 2013; Rendeiro et al., 2012, 2013; Williams
et al., 2008).
Despite clear evidence regarding the acute vascular effects of
ﬂavonoids shown in humans (Macready et al., 2010) and medium-
term changes in synaptic plasticity markers demonstrated in
animal studies (Spencer, 2009), the basic mechanisms of action
of ﬂavonoids in humans remains unclear, due to a lack of precise
causative/mechanistic data. Future work should strive to determine
the mechanistic basis of ﬂavonoids-induced improvements in cog-
nitive function by investigating the degree to which peripheral-
and cerebral blood ﬂow induced by ﬂavonoids metabolites plays
in determining improvements in human cognitive performance, in
particular attention and episodic memory.
5.6. Vitamins
Among vitamins, high dietary intakes of tocopherols are associ-
ated with a reduced AD or dementia incidence (Mangialasche et al.,
2011). However, interventional studies using Vitamin E supple-
mentation failed to report positive effects on the risk of AD (Barnard
et al., 2014) for vitamin C, although there has been inconsistency
among observational studies relating dietary intake of ascorbic acid
to improved cognition, some results have favoured an important
role for ascorbic acid in cognitive health. Therefore, further research
focused on investigating the speciﬁc role of ascorbic acid in AD with
special attention to the study design and methodologies, which rep-
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esent an important study limitation, has been suggested to provide
ore conclusive data (Harrison et al., 2014).
The mechanisms that support the relation between vita-
ins B and the brain are mostly related to homocysteine (Hcy)
etabolism, a marker of vitamin B insufﬁciency. Hcy is catabolized
hrough a remethylation cycle mediated by folate and vitamin B12,
hich provides methyl-group for several metabolic steps (Levitt
nd Karlinsky, 1992). Clinical evidence has demonstrated a cor-
elation between elevated plasma (Hcy) and the occurrence of
D and thus, hyperhomocysteinemia has been suggested as an
mportant risk factor of AD (Obeid and Herrmann, 2006; Seshadri
t al., 2002). Observational studies have reported that people with
igh blood concentrations of Hcy have elevated risk for vascular
isease (Clarke et al., 1991) and AD (Clarke et al., 1998). These
tudies prompted randomized trials to assess whether vitamins
 positively impacted on cognition, but their results have been
ixed. In one of the most recent systematic reviews, 35 cohort
tudies with a total number of 14,235 individuals were iden-
iﬁed (O’Leary et al., 2012). Twenty-one studies were of good
uality of which only 7 showed a beneﬁcial association. This asso-
iation was more consistent in studies that included the newer
nd more speciﬁc markers of vitamin B12 status such as methyl-
alonic acid (MMA)  and holotranscobalamin (holoTC). The most
ecent Alzheimer’s Disease International (ADI) report on nutri-
ion and dementia included 4 additional studies that all showed
 beneﬁcial association of a higher vitamin B status with less cog-
itive decline (Alzheimer’s Disease International, 2014). Even after
ncluding those more recent studies still the majority of observa-
ional studies did not show a beneﬁcial association. A meta-analysis
as performed on RCTs performed in individuals with or with-
ut cognitive impairment (Ford and Almeida, 2012). Nineteen RCTs
ere included and the overall conclusion was that no effect of vita-
in  B supplementation was observed on cognition. Similar ﬁndings
ere reported in an earlier Cochrane review (Malouf and Areosa
astre, 2003), which concluded that 4 RCTs provided no evidence
or improvement in people with cognitive impairment or demen-
ia when treated with folic acid with or without vitamin B12 or
6. However, a later Cochrane update (Malouf and Grimley Evans,
008), which included 8 studies concluded that there was  some
ffect. For instance, a better response to cholinesterase treatment
ith B vitamins was observed in some studies including both peo-
le with AD and without dementia.
After these reviews some additional RCT results were published
Douaud et al., 2013; Hankey et al., 2013; Walker et al., 2012) of
hich two RCTs showed an effect. Several observational studies
ave included brain MRI  and all showed at least some beneﬁcial
ssociations (de Lau et al., 2009; Sachdev et al., 2002; Smith et al.,
010; Tangney et al., 2011; Vogiatzoglou et al., 2008).
Some other conﬂicting results have been released by the Folate
fter Coronary Intervention Trial (FACIT) (n = 800) which reported
hat folic acid had a signiﬁcant effect on memory (Durga et al.,
007). This study showed that people who were treated with folic
cid and had high levels of Hcy (which is a risk factor for dementia
nd heart disease) had better cognitive function over a 2–3 years
eriod than those who were not treated.
One recent RCT (VITACOG trial) including 168 MCI patients has
een performed that included brain MRI  as an outcome measure
nd showed that after 24 months of vitamin B supplementation
atients showed a 30% slower rate of brain atrophy (Smith et al.,
010). Additionally, in the same study it was demonstrated that
itamin B supplementation was able to slow the cognitive and
linical decline in people with MCI, in particular in those with
levated Hcy levels (de Jager et al., 2012). Despite this, reliable evi-
ence requires large trials, avoidance of bias and sub-group analysis
nd meta-analyses of such trials. A recent meta-analysis by Clarke
t al. (Clarke et al., 2014) included all B-vitamin trials assessingReviews 35 (2017) 222–240 231
effects on cognitive function. It assessed the effects of B-vitamins
on individual domains of cognitive function, global cognitive func-
tion and cognitive ageing. Dietary supplementation with vitamins B
to lower Hcy levels had no signiﬁcant effect on individual domains,
global cognitive function or cognitive ageing. Overall, it was  shown
that vitamins B had no beneﬁcial effect on either cognitive ageing
(Clarke et al., 2014) or vascular disease (Clarke et al., 2010).
Another vitamin that has been widely investigated is vitamin
D. Currently a large proportion of populations are vitamin D deﬁ-
cient, and in particular the elderly (van der Wielen et al., 1995).
Some vitamin D receptors are located in the brain and many mech-
anisms that may  support its role in the brain have been identiﬁed
(Brouwer-Brolsma and de Groot, 2015). Regarding observational
evidence, Balion et al. (2012) identiﬁed 37 studies that could be
included in his meta-analysis. There was a large heterogeneity, in
particular in different cognitive tests that were used as an outcome
measure. Results based on 8 studies using the MMSE  showed that
participants with 25-hydroxyvitamin D (25(OH)D) concentrations
>50 nmol/L had a higher MMSE  score than those with concentra-
tions <50 nmol/L.
5.7. -3 PUFAs
Long-chain -3 PUFAs, EPA and DHA have been associated with
decreased brain inﬂammation and preservation of the integrity and
function of neuronal membranes (Janssen and Kiliaan, 2014).For
example, DHA which is a key component of phospholipid cell mem-
branes, may  modulate the amyloid precursor protein (APP), thereby
reducing formation and increasing clearance of -amyloid, the
main component of AD plaques (Alzheimer’s Disease International,
2014).
Observational evidence has been focused on the association
between ﬁsh long-chain -3 PUFA intake or -3 PUFA status and
cognitive functioning, cognitive decline or dementia. More than 30
studies have been performed and the vast majority of studies have
showed beneﬁcial associations (van de Rest et al., 2012). In the ﬁrst
Cochrane review on -3 PUFA trials that was  published in 2006,
no single RCT could be included (Lim et al., 2006). That review was
updated in 2012 and at that time the ﬁrst RCTs in non-demented
elderly and with a study duration of at least 6 months were pub-
lished. In total, three RCTs were included with a total of 3536
participants. The conclusion was that -3 PUFA supplementation
had no effect on cognitive functioning (Sydenham et al., 2012). In
the same year Mazereeuw et al. (2012) performed a meta-analysis
and included cognitively impaired and demented individuals as
well. They included 10 RCTs and did not see an overall beneﬁt
for immediate recall after -3 PUFA supplementation in healthy
or demented elderly. However, they found an effect on the speciﬁc
cognitive domains for immediate recall, attention and processing
speed in cognitively impaired non-demented individuals.
The research ﬁeld is currently advancing by not only the inclu-
sion of batteries of cognitive tests as an outcome measure, but also
including MRI  techniques. Several observational studies including
brain MRI  have been performed and all have showed at least some
beneﬁcial associations (Conklin et al., 2007; Pottala et al., 2014;
Samieri et al., 2012; Tan et al., 2012; Titova et al., 2013; Virtanen
et al., 2008). Also, one RCT has been performed in 65 healthy elderly
and with a study duration of 26 weeks (Witte et al., 2013). In this
study beneﬁcial effects were found on executive functioning, on
the MRI  measures of gray matter atrophy, and on white matter
microstructural integrity.5.8. Calorie restriction
Diet including total intake, frequency, and content has emerged
as an important environmental factor that can impact brain plas-
2 earch
t
a
A
t
n
l
s
e
a
h
t
A
c
s
t
n
a
i
t
e
C
o
t
t
i
s
e
o
b
t
t
m
a
t
o
t
5
f
p
w
t
p
d
n
b
p
d
m
r
t
r
r
(
s
e
a
k
a
s
a
r
p32 D. Vauzour et al. / Ageing Res
icity, including adult hippocampal neurogenesis (AHN) (Stangl
nd Thuret, 2009; Zainuddin and Thuret, 2012). The level of
HN decreases with age and has been linked directly to cogni-
ion and mood (Murphy et al., 2014). In rodents, an increase of
eurogenesis in the hippocampus is associated with improved
earning/memory abilities, whereas a decrease is associated with
ymptoms of depression (Mateus-Pinheiro et al., 2013; Snyder
t al., 2011). Therefore, modulation of AHN by diet emerges as
 potential mechanism by which nutrition impacts on mental
ealth (Murphy et al., 2014). Synapse formation is a key site in
he initiation of the neurodegenerative process occurring during
D pathology, and then, calorie restriction (CR) may  have signiﬁ-
ant effects on the disease pathology via modulation of AHN and
ynaptic plasticity (Maruszak et al., 2014). Wu et al. (2008b) found
hat CR (30% for 4 months) in the transgenic mouse model of AD sig-
iﬁcantly attenuated ventricle enlargement, hippocampal atrophy,
nd caspase-3-activation. For example, the effect of CR, limiting the
ntake compared to baseline unrestricted or ad libitum consump-
ion, together with maintained levels of vitamin, mineral, or other
ssential biomolecules has appeared to increase AHN. Furthermore,
R seems to improve the resilience of synapses to metabolic and
xidative damage and modulates the structure and functional sta-
us of synapses (Mattson, 2012). Moreover, CR has demonstrated
o induce the differential expression of genes of which 25% are
nvolved in synaptic plasticity (Park and Prolla, 2005). Mice have
howed improved working memory after long-term CR (Kuhla
t al., 2013; Steinman et al., 2011). An increase in the expression
f NMDA receptors, essential for LTP and synaptic plasticity, has
een found in the hippocampus of 60% CR obese rats as compared
o age-matched ad libitum fed animals (Yilmaz et al., 2011). Taken
ogether, while still further research is warranted to elucidate the
echanisms by which some dietary factors induce brain plasticity,
nimal and supported epidemiological studies have demonstrated
hat multiple dietary regimens and components increase the levels
f AHN, enhance brain plasticity and promote synaptic function in
he context of ageing.
.9. Ketogenic diets
Very-low-carbohydrate ketogenic diets (VLCKD) have been used
or many decades especially after the 1970s when they became
opular for weight loss (Atkins, 1972). But it was in the early 1920s
hen the importance of the use of these diets became relevant from
he clinical point of view and were successfully used to treat many
athological conditions such as epilepsy (Hartman et al., 2007),
iabetes (Dashti et al., 2006), CVD factors (Paoli et al., 2011) and
eurological diseases (Baranano and Hartman, 2008). The review
y Paoli et al. (2013) considers possible mechanisms for the thera-
eutic actions of the ketogenic diet (KD) on weight reduction and
ifferent diseases such as CVD and diabetes. Although, the exact
echanisms of action of the KD are still poorly understood recently
eports have suggested that ketone bodies (KB) act as neuropro-
ective agents by raising ATP levels, diminishing the production of
eactive oxygen species in neurological tissues and enhancing the
egulation of synaptic function though mitochondrial biogenesis
Bough and Rho, 2007). Moreover, the stimulation of PUFAs synthe-
is by a KD has been demonstrated to regulate neuronal membrane
xcitability mediated by voltage-gated sodium channels (Huffman
nd Kossoff, 2006).
However, new research concerning one of these diets, the MCT
etogenic diet, has recently demonstrated a compelling mech-
nism of action in seizure control (Chang et al., 2015). These
tudies show that a fatty acid provided in the diet, decanoic
cid (10:0), reduces seizures induced in hippocampal slices of
odent. Using the whole cell patch clamp with rat hippocam-
al slices, decanoic acid reduced excitatory postsynaptic currents Reviews 35 (2017) 222–240
by 38.9 ± 5.5% at 52 g/mL concentration and inhibited -amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors,
which are a target for antiepileptic drugs. This inhibitory mecha-
nism is speciﬁc to deﬁned chemical structures, is effective against
multiple AMPA subunit compositions, and is enhanced during
synaptic activation. These results deﬁne how the MCT diet provides
a way of controlling seizures by the diet, without the need for the
production of ketones or for pharmacological intervention (Chang
et al., 2015, 2013).
Given that patients with AD show a higher incidence of seizures
(Palop and Mucke, 2009), KD may  be a successful diet for its clin-
ical treatment. Supporting evidence suggests that acute elevation
of serum -hydroxibutyrate (-OHB) (one type of KB) through an
oral dose of MCTs shows cognitive improvements in AD patients.
A recent RCT in 20 patients (55–58 years) diagnosed with prob-
able AD (n = 15) or MCI  (n = 5) showed that acute administration
of MCTs (40 g), which led to elevate -OHB, was  positively corre-
lated to improved cognitive function (Reger et al., 2004). Another
clinical trial performed in 152 patients with mild to moderate AD
(Henderson et al., 2009) compared the effect of Axona®, a medi-
cal food containing a formulation of MCTs, or placebo and found
that cognitive scores remained stabilized in the Axona® group,
while the placebo groups presented a decline in cognition, but only
among Apo4(−)  subjects. Although, Axona® formulation has been
reported to be well-tolerated in normal elderly volunteers, the pro-
posed cognitive effect is uncertain in non-demented elderly people.
Importantly, all these cognitive responses to increased energetic
substrates were strongly dependent on APOE genotype (Craft et al.,
2000).
5.10. Multicomponent diets
The important role of diets and healthy lifestyle in the preven-
tion of vascular disease development is widely accepted. Already
30 years ago pioneering studies on Greenland Eskimos indicated
that intake of -3 long chain polyunsaturated fatty acids (-3 LCP-
UFAs) from ﬁsh and wildfowl had protective effects against CVD
(Bang et al., 1971, 1980). More recently, the Mediterranean diet
containing ﬁsh, olive oil and nuts as important lipid containing
components, has been shown in several prospective worldwide
studies to be inversely associated with CVD (Estruch et al., 2013)
and to have a strong protective function against hypertension, obe-
sity, and AD risks (Calton et al., 2014; Grosso et al., 2014; Koliaki and
Katsilambros, 2013; Scarmeas et al., 2009). Moreover a recent thor-
ough systematic review and meta-analysis suggests that a higher
adherence to the Mediterranean diet may  affect not only the risk of
AD, but is also associated with a reduced risk of developing MCI  and
AD, and a reduced risk of progressing from MCI  to AD (Singh., et al.,
2014; Solfrizzi and Panza, 2014).Dietary lipids are also starting to
be highly recognized in nutrition thanks to their direct actions on
synaptic function and cognitive processes (de Waal et al., 2014;
Kamphuis and Scheltens, 2010; Shah, 2011; Shah et al., 2013; van
Wijk et al., 2014; Wurtman, 2008). Contrarily, diets high in satu-
rated fat are becoming notorious for reducing molecular substrates
that support cognitive processing and increasing the risk of neuro-
logical dysfunction in both animals and humans (Gomez-Pinilla,
2008; Li et al., 2013; Wu et al., 2008a). Dietary factors can affect
multiple brain processes by regulating neurotransmitter pathways,
synaptic transmission, membrane ﬂuidity and signal-transduction
pathways. Recent data published by the group of Kiliaan et al.
(Jansen et al., 2014; Wiesmann et al., 2013; Zerbi et al., 2014) and
latest data in mice models for AD and vascular impairment, have
shown that the treatment with multicomponent diets promotes
neuroprotection by decreasing inﬂammation, restoring cerebral
blood ﬂow and volume, inhibiting neurodegeneration, and enhanc-
ing neural plasticity by increasing neurogenesis (Wiesmann et al.,
earch 
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016). In particular, they (Zerbi et al., 2014) showed that a speciﬁc
ombination diet (FortasynTM) containing membrane precursors
uch as -3 fatty acids and uridine monophosphate plus cofac-
ors for membrane synthesis was able to inhibit/reverse the early
unctional connectivity reduction and cerebral blood ﬂow (CBF)
mpairment in mice (both parameters were apparent already before
ognitive decline).
Thus, diet may  serve as preventive strategy at very early,
on-symptomatic phases of AD, especially because there are no
urrently effective treatments for AD. Therefore, future research
hould focus on the early, asymptomatic phase of the disease
specially on the (cardio) vascular risk factors like atherosclero-
is, hypertension, obesity and T2DM being modiﬁable via changes
n lifestyle factors such as diet.
.11. Exercise
Gradual and progressive memory decline is often one of the ear-
iest hallmarks in AD which can strongly inﬂuence the quality of life
f an individual. Several lifestyle factors may  interfere with the rate
f cognitive decline in the elderly such as diet and physical activity.
The Study of Elderly’s Memory impairment and Associated Risk
actors (SEMAR) has been set up in Indonesia and included 719
articipants (aged 52–99 years) from different ethnic backgrounds
n rural and urban Java (Jakarta, Citengah and Yogyakarta) (unpub-
ished data). These cohorts as well as other similar cohorts in China,
etherlands, UK and USA, have recently been set up to investi-
ate whether lifestyle factors in different ethnic/cultural cohorts
ere associated with a reduced risk of dementia (ongoing study)
nd found that the combination of exercise and eating fruit had
 cumulative effect in reducing dementia risk in Indonesia people
unpublished data).
Many observational studies (Clifford and Hagervorst, 2009;
ogervorst et al., 2012) have showed a reduced risk of dementia
n people who exercise. For instance, in Indonesia it was  found that
lder people who engaged in sports had a halved risk of demen-
ia (Hogervorst et al., 2012), which was similar to data from the
S and other countries (Barnes and Yaffe, 2011). However, several
eviews have also showed that only 50% of the studies including an
xercise intervention showed cognitive improvement in older peo-
le (Clifford and Hagervorst, 2009; Hogervorst et al., 2012) which
ight be due to poor adherence to the program. Similarly, the
roup of Hogervorst et al. (2012) found that resistance band (mus-
le strength) exercises 2–3 times/week for 20–30 min  improved
emory function. In addition, exercise may  be effective as a pre-
entive activity as it can lower blood pressure and total cholesterol,
an reduce abdominal fat and improve immune and lung function,
s well as improve cardiovascular function, which improves cere-
ral blood ﬂow. As discussed previously, all these factors may  be
mplicated in dementia. Importantly, exercise can also directly pro-
ote outgrowth of nerve cells which allows better communication
etween brain cells, which is often reduced in dementia (Clifford
nd Hagervorst, 2009). Even in people who have already developed
ementia, walking and muscle strengthening exercises are likely to
ave positive effects on cognitive abilities (Hogervorst et al., 2012).
In conclusion, risk factors for AD are similar to those for CVD
heart), such as high blood pressure, smoking, high cholesterol and
besity and need to be treated in midlife at the latest to reduce
he risk of dementia later in life. A multi-disciplinary change in
ifestyles (combining exercise with healthy diets) with a focus on
idlife is the most important factor for prevention of dementia.
herefore, changing the lifestyle to a healthier one which includes
xercise and a healthy diet can reduce the risk for both heart disease
nd dementia.Reviews 35 (2017) 222–240 233
6. Methodological challenges in nutritional interventions
on cognition
Epidemiological studies have shown that a lower risk of demen-
tia or cognitive decline is associated with diets relatively low in
energy (Luchsinger et al., 2002) but rich in several key nutrients
and food derived non-nutrient bioactives, including long-chain -
3 PUFA (Cunnane et al., 2009; Dacks et al., 2013), vitamins B (Clarke,
2008), antioxidants such as vitamins C, E (Mangialasche et al., 2010)
and carotenoids (Li et al., 2012), and polyphenols (Joseph et al.,
2009). However, most RCTs that have administered these dietary
components as supplements have yielded disappointing results on
cognition so far, (Barberger Gateau et al., 2013; Clarke et al., 2014;
Sydenham et al., 2012). There are, however, some notable interest,
particularly in the Memory Improvement with DHA Study (MIDAS)
(Yurko-Mauro et al., 2010), the Souvenaid® combination of nutri-
ents in mild AD (Olde Rikkert et al., 2015; Scheltens et al., 2010,
2012), and the Prevention with Mediterranean Diet (PREDIMED)
study (Valls-Pedret et al., 2015). Thus, epidemiological data and
these “success stories” from a limited number of RCTs, provide the
justiﬁcation and valuable methodological insight. In addition, they
could be used in combination with the implementation of more
robust ‘ﬁt-for-purpose’ RCTs to demonstrate the impact of diet on
cognition in older persons. Such interventions should be carefully
powered and of adequate duration (chosen based on physiologi-
cal insights into likely changes in the primary outcome measures
during the intervention period) in order to prevent false negative
ﬁndings. Three further aspects should be considered: 1) improv-
ing inclusion criteria in RCTs, 2) optimizing the composition of the
nutritional supplement or the diet to be evaluated, and 3) deﬁning
more sensitive primary and secondary outcomes which are also
important methodological considerations that will be discussed
below.
Identiﬁcation of individuals at high risk of cognitive decline or
dementia, who  should be included in RCTs assessing the impact
of nutrition, who  are likely to be sensitive and gain most beneﬁt
from the intervention should be based on early markers of dis-
ease progression, low dietary intake or blood levels of selected
dietary components of interest, or genetic characteristics. The nat-
ural history of the pathophysiology of AD spreads over decades
during which A accumulates in the brain before the ﬁrst cognitive
symptoms appear (Jack et al., 2013, 2010a,b) raising the question
of the optimal window for prevention or the progression from the
preclinical, ‘at-risk’ phase to a clinical diagnosis of disease. It is
virtually impossible to demonstrate the efﬁcacy of primary pre-
vention in regard to cognitive decline. Thus, the main target of
RCTs should be the secondary prevention, at a very early stage of
cognitive decline. The MIDAS included middle-aged adults (aged
55 years) with a subjective memory complaint and preserved gen-
eral cognitive function but a logical memory baseline score lower
than that of normal younger adults (Yurko-Mauro et al., 2010) to
explore the effect of DHA consumption (900 mg/day) for 24 weeks.
These individuals also had low regular ﬁsh consumption, less than
200 mg/day DHA. After completion of the trial, those receiving DHA,
scored signiﬁcantly higher on several tests of memory than the con-
trol group. The use of genetic variation as an inclusion/exclusion
criteria could also be considered, since several epidemiological
studies and at least one RCT have suggested that the beneﬁt of
supplementation with DHA on cognition could be limited to non-
carriers of the 4 allele of the APOE4 gene, the main genetic risk
factor for AD (Barberger Gateau et al., 2011).
Epidemiology also allows characterization of healthy diets
providing optimal combinations of foods and nutrients that are
associated with better cognitive performance (Alles et al., 2012),
providing the rationale for RCTs using combinations of supple-
ments rather than single nutrients. The most famous example is the
2 earch Reviews 35 (2017) 222–240
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Table 1
Contribution of epidemiology to design more efﬁcient RCTs assessing the impact of
nutrition on cognition.
What epidemiology tells us What RCTs should do
Lower intake or blood levels of
some nutrients are associated
with higher risk of cognitive
decline or dementia
⇒ Target individuals with speciﬁc
nutritional insufﬁciency, based on
dietary or biological data
Signiﬁcant cognitive decline is a
late event in neurodegenerative
diseases
⇒Target at risk individuals with
more sensitive neuropsychological
tests and biomarkers
Interaction between -3 PUFA
status and APOE4
⇒Stratify RCTs according to APOE4
genotype and probably other single
nucleotides polymorphisms (SNPs)
Healthy diets are associated with
lower risk of cognitive decline or
AD
⇒Use  dietary supplements
providing similar combinations of
nutrients
AD  is a multi-factorial disease
whose natural history spreads
over decades
⇒Use early and speciﬁc outcomes:
– biomarkers of disease
progression
– biomarkers of mechanisms of
action (oxidative stress,
inﬂammation, insulin resistance,
lipids.  . . etc.) in combination34 D. Vauzour et al. / Ageing Res
editerranean diet, which has been associated with lower risks of
ementia or cognitive decline in several epidemiological studies,
ostly in Europe and the US (Feart et al., 2010; Lourida et al., 2013;
an de Rest et al., 2015). However, there is great heterogeneity in
he deﬁnition of the “Mediterranean diet” between studies espe-
ially in non-Mediterranean countries. The PREDIMED NAVARRA
CT in Spain, demonstrated that randomized participants who fol-
owed a Mediterranean diet enriched with virgin olive oil or nuts
cored signiﬁcantly better than the control group following a low-
at diet on a global cognitive score 6.5 years later (Valls-Pedret et al.,
015). Few RCTs have evaluated the impact of multivitamin supple-
ents on cognition (Grima et al., 2012). For instance, Souvenaid®
hich contains -3 PUFA (EPA and DHA), B-vitamins, a mixture of
ntioxidants, and uridine monophosphate (UMP), was formulated
o improve synapse formation and function (Cansev et al., 2015;
urtman et al., 2009). A 24-week RCT conducted in patients with
ild AD showed that the group receiving Souvenaid® scored signif-
cantly better than the placebo group on the memory domain of the
europsychological test battery, the primary outcome (Scheltens
t al., 2012). The study also showed improvement on measures
f functional connectivity (Scheltens et al., 2012), functional brain
etwork organization (de Waal et al., 2014), and sustained mem-
ry improvement until 48 weeks in an open label extension study
Olde Rikkert et al., 2015). This was the second study in mild AD
ith this intervention and conﬁrmed the results of a proof-of-
oncept study which showed improved memory performance after
2 weeks (Scheltens et al., 2010). As these studies were conducted
n subjects with early AD, more research is needed to deﬁne the
ptimal combination and doses of nutrients that could contribute
o delay cognitive decline in older persons without AD diagnosis.
In the case of EPA + DHA, vitamin D and B vitamins, although
here is relatively consistent epidemiological evidence to exhibit
heir independent impacts on cognition, RCTs have generally failed
o demonstrate any efﬁcacy.
Identiﬁcation of relevant and sensitive biomarkers of disease
rogression, based on knowledge of the speciﬁc molecular and
hysiological targets of the intervention of interest, can optimize
he choice of primary and secondary outcomes in RCTs. MRI  and
MRI can provide evidence of the impact of nutrients on brain
tructure and function The rate of brain atrophy was the pri-
ary outcome of the Hcy and B vitamins in cognitive impairment
VITACOG) study (Smith et al., 2010) which found that vitamin
 intake in the active treatment group was associated with 30%
ess brain atrophy per year than in those receiving the placebo.
he effect on brain atrophy and cognitive function was  mainly
bserved in those with higher baseline homocysteine levels, which
ere lowered by vitamin B treatment (de Jager et al., 2012; Smith
t al., 2010). However, some RCTs have yielded discordant results
egarding their impact on mechanisms of action and cognition. The
oncentration of F2-isoprostane in CSF, a marker of oxidative stress
lipid peroxidation), has been proposed as a sensitive but not spe-
iﬁc biomarker of age-related brain injury (Li et al., 2014). In an RCT,
8 patients with mild to moderate AD were randomized to receive a
igh dose antioxidant mixture (800 IU/d vitamin E, 500 mg/d vita-
in  C, and 900 mg/day -lipoic acid) or 400 mg/d Coenzyme Q,
nother antioxidant compound, or a placebo (Galasko et al., 2012).
fter 16 weeks, those receiving the antioxidant mixture had sig-
iﬁcantly decreased F2-isoprostanes in CSF as expected, but an
ccelerated cognitive decline. Thus, biomarkers should always be
sed in combination with cognitive outcomes.
This lack of positive results in RCTs may  be due to too short trial
uration, not appropriate target group, use of an inadequate dose,
ack of efﬁcacy of single nutrients and/or not sufﬁciently sensitive
ethodology to measure the outcomes. However, the identiﬁca-
ion of all these limitations will allow a better performance of future
ntervention trials. In addition, there is still need for well-designedwith cognitive outcomes
trials that: a) have long intervention periods (at least >1.5 year), b)
target at risk groups (mild cognitively impaired or nutrient deﬁ-
cient subjects), c) use harmonized cognitive test batteries (de Jager
et al., 2014), d) include biomarkers and/or imaging measures, e)
use a multi-nutrient or food pattern approach or a multi-domain
approach, and f) whose design is aligned with speciﬁc mechanisms.
Findings from epidemiological studies can be used to design more
efﬁcient RCTs assessing the impact of combinations of nutrients
in well-targeted individuals, using both biomarkers and cognitive
assessment as outcomes (Table 1).
7. Conclusion
Decline in cognitive abilities with age occurs in healthy indi-
viduals throughout the adult lifespan. Moreover, the line between
normal and pathological ageing is not well-deﬁned as neuro-
logical diseases start years before any clinical symptoms arise.
Several health conditions such as CVD, diabetes or obesity are
closely related to cognition. Therefore, when identifying dietary
approaches to promote healthy brain ageing a holistic approach
should be considered including nutrition, exercise and lifestyle
factors, which not only target the brain but also overall cardio-
metabolic health (Fig. 1).
The mechanisms associated with normal ageing, including
oxidative stress, neuroinﬂammation and vascular dysfunction are
the same as those contributing to the development of neurological
diseases. However, in these pathological conditions, the mecha-
nisms contributing to ageing are exacerbated and triggered by
different factors which might be genetic or environmental.
Preclinical studies in animals have consistently demonstrated
the positive impact of several dietary components on cog-
nitive performance and epidemiological studies have showed
successful association of select dietary patterns with cognitive
status. Particularly there is reasonable evidence that consuming
Mediterranean-style diets protects against cognitive impairment.
RCTs approaches have showed mixed results with intervention
with single dietary components generally disappointing while
some multi-nutrient/non-nutrient interventions have yielded
more encouraging results. These observations are consistent with
the results from epidemiological studies indicating that an adher-
ence to dietary patterns, rather than adequate intake of single
D. Vauzour et al. / Ageing Research Reviews 35 (2017) 222–240 235
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ietary components may  be the most effective means of protecting
gainst cognitive decline. A major objective of future research is
o deﬁne the nutritional requirement for healthy cognitive ageing,
nd to translate these into effective dietary recommendations.
RCTs are the gold standard to probe the efﬁcacy of drugs but
t may  not be the same for dietary components. In terms of pri-
ary prevention, it is logistically difﬁcult to establish the effect
f nutrition on cognition through RCTs which would require par-
icipants follow up for potentially decades. In terms of secondary
revention, targeting individuals at high risk of cognitive decline
nd learning from epidemiology as suggested in the last section of
his review should allow a relatively rapid impact on cognition to
e established.
Finally, it is the aim of this group to continue with the revision of
he state of the art on nutrition for the ageing brain by organizing a
ollow-up workshop. In particular, mechanisms of ageing and their
nteraction with nutrients will be revisited, and new avenues and
echanisms of cognitive ageing that may  be inﬂuenced by nutrition
ill be identiﬁed.
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